Alefacept for Severe Alopecia Areata: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial

A multicenter, double-blind, randomized, placebo-controlled clinical trial involving 45 individuals with severe alopecia areata (AA) assessed the efficacy of alefacept, a T-cell biologic inhibitor. Participants received alefacept for 12 weeks, but results showed no statistically significant improvement in the Severity of Alopecia Tool (SALT) score compared to the placebo group (P = .70). The study concluded that alefacept was ineffective for treating severe AA.